➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
Harvard Business School
Baxter
Merck
Boehringer Ingelheim

Last Updated: May 6, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR REBECCAMYCIN

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Clinical Trials for Rebeccamycin

Trial ID Title Status Sponsor Phase Summary
NCT00003737 Rebeccamycin Analog in Treating Children With Relapsed or Refractory Neuroblastoma Completed National Cancer Institute (NCI) Phase 2 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of rebeccamycin analog in treating children who have relapsed or refractory neuroblastoma.
NCT00003737 Rebeccamycin Analog in Treating Children With Relapsed or Refractory Neuroblastoma Completed Memorial Sloan Kettering Cancer Center Phase 2 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of rebeccamycin analog in treating children who have relapsed or refractory neuroblastoma.
NCT00004189 Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer Completed National Cancer Institute (NCI) Phase 1 Phase I trial to study the effectiveness of rebeccamycin analog and cisplatin with or without filgrastim in treating patients who have advanced cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy.
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for Rebeccamycin

Condition Name

Condition Name for
Intervention Trials
Neuroblastoma 2
Lymphoma 2
Unspecified Adult Solid Tumor, Protocol Specific 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for
Intervention Trials
Lymphoma 2
Neuroblastoma 2
Lung Neoplasms 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Rebeccamycin

Trials by Country

Trials by Country for
Location Trials
United States 62
Canada 8
Australia 5
New Zealand 1
Netherlands 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for
Location Trials
Ohio 5
Texas 3
New York 3
Michigan 3
Illinois 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Rebeccamycin

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 2 9
Phase 1 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Completed 8
Terminated 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Rebeccamycin

Sponsor Name

Sponsor Name for
Sponsor Trials
National Cancer Institute (NCI) 12
Case Comprehensive Cancer Center 2
Northwestern University 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for
Sponsor Trials
NIH 12
Other 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Harvard Business School
Mallinckrodt
Moodys
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.